Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (symbol: MIRM) is a biopharmaceutical company headquartered in Foster City, California. Established in 2018, the company focuses on the development and commercialization of innovative therapies aimed at treating debilitating liver diseases. Mirum Pharmaceuticals is dedicated to addressing rare and orphan diseases, making significant strides in this niche sector of the healthcare market.
At the core of Mirum Pharmaceuticals' product pipeline is Maralixibat, an investigational oral drug currently in phase 3 clinical trials. Maralixibat is being studied for its efficacy in treating several severe liver conditions, including Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia. This product represents a potential breakthrough in providing therapeutic options for these challenging conditions.
In addition, the company has developed Volixibat, a drug aimed at treating Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC). These ongoing projects highlight Mirum Pharmaceuticals' commitment to advancing the treatment landscape for liver diseases with significant unmet medical needs.
Mirum Pharmaceuticals has achieved notable milestones, such as the approval of Livmarli, an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS), providing much-needed relief for those affected by this condition.
The company stands out for its strategic approach to identifying, acquiring, and developing novel therapies. It has established partnerships and collaborations to bolster its research endeavors and expand its reach in the biopharmaceutical industry. With a robust pipeline and a clear focus on debilitating liver diseases, Mirum Pharmaceuticals continues to make significant progress in its mission to improve patient outcomes and quality of life.
For the latest news and updates about Mirum Pharmaceuticals, including recent achievements, ongoing projects, and financial performance, investors and stakeholders can rely on resources like StockTitan for comprehensive and timely information.
Stay informed about Mirum Pharmaceuticals, Inc. and its groundbreaking work in the biopharmaceutical sector, and keep track of the latest developments and stock performance on StockTitan.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement grants approved by its Compensation Committee on December 10, 2024. The grants include 48,400 non-qualified stock options and 24,200 restricted stock units (RSUs) awarded to five new employees under the company's 2020 Inducement Plan.
The stock options, priced at $44.10 per share, will vest over four years with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (NASDAQ: MIRM) announced its participation at AASLD's The Liver Meeting, scheduled for November 15-19, 2024, in San Diego. The company will present multiple clinical studies including the VANTAGE trial studying volixibat for primary biliary cholangitis, MARCH-ON trial data on Progressive Familial Intrahepatic Cholestasis, and research on LIVMARLI (maralixibat). Presentations will cover various aspects including pruritus improvements, caregiver burden, real-world usage in biliary atresia, and bile acid correlations. The event will also feature a fireside discussion with a physician and an ALGS patient sharing experience with LIVMARLI.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported third-quarter 2024 financial results, showcasing a significant growth in net product sales, reaching $90.3 million, an 89% increase compared to Q3 2023. The company has raised its 2024 guidance to $330 - 335 million. Key developments include the breakthrough therapy designation for volixibat in PBC, with interim results to be presented at the AASLD Liver Meeting 2024. The PDUFA date for chenodiol in CTX is set for December 28, 2024. Mirum also in-licensed global rights to the PDE4D inhibitor MRM-3379, targeting Fragile X syndrome, with a Phase 2 study initiation expected in 2025. As of September 30, 2024, Mirum's cash, cash equivalents, and investments totaled $293.8 million. Operating expenses for Q3 2024 were $103.1 million, up from $72.9 million in Q3 2023. A business update conference call is scheduled for November 12, 2024.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement awards granted by its Compensation Committee to seven new employees on November 8, 2024. The awards include 56,100 non-qualified stock options at $42.00 per share and 28,050 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both awards require continued employment and were granted under Mirum's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in three upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference on November 19th at 10:20 a.m. ET, the 7th Annual Evercore HealthCONx Conference on December 3rd at 2:10 p.m. ET, and Citi's 2024 Global Healthcare Conference on December 4th. Interested parties can access webcast links and additional information through Mirum's corporate website under the Investors and Media section.
Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its third quarter 2024 financial results announcement and conference call for November 12, 2024. The conference call will take place at 8:30 a.m. ET / 5:30 a.m. PT, accessible via toll-free dial-in for U.S. participants and international lines. A webcast option will be available through the company's website, with a replay accessible for 30 days following the event.
Mirum Pharmaceuticals announced its participation in the NASPGHAN annual meeting (November 6-9, 2024) in Hollywood, Florida, where it will present LIVMARLI® (maralixibat) data for Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) treatments. The presentations will showcase clinical benefits and real-world evidence, including improvements in growth for PFIC patients, 7-year durability of benefits in ALGS patients, liver health improvements, enhanced quality of life, and impact on concomitant medication use for cholestatic pruritus treatment.
Mirum Pharmaceuticals (NASDAQ: MIRM) has announced inducement awards granted to four new employees on October 10, 2024. The awards, approved by the Compensation Committee of Mirum's Board of Directors, include:
1. Non-qualified stock options to purchase 34,100 shares of common stock
2. 17,050 restricted stock units (RSUs)
The stock options have an exercise price of $38.48 per share, matching Mirum's closing trading price on October 10, 2024. They will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both are subject to continued employment with Mirum and the terms of the 2020 Inducement Plan and applicable award agreements.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced that the FDA has granted Breakthrough Therapy Designation to volixibat for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). This designation is based on positive interim results from the Phase 2b VANTAGE study, which showed statistically significant improvement in pruritus compared to placebo. The study's confirmatory portion is ongoing, with enrollment expected to complete in 2026.
The Breakthrough Therapy Designation aims to expedite the development and review of drugs for serious diseases, requiring preliminary clinical evidence of substantial improvement over existing therapies. Mirum's chief medical officer, Dr. Joanne Quan, emphasized the importance of addressing PBC-related itch and the company's commitment to making volixibat available to patients as quickly as possible.
Mirum Pharmaceuticals (NASDAQ: MIRM) has granted inducement awards to seven new employees on September 10, 2024. The awards, approved by the Compensation Committee of Mirum's Board of Directors, consist of:
- Non-qualified stock options to purchase 19,700 shares of common stock
- 9,850 restricted stock units (RSUs)
The stock options have an exercise price of $41.77 per share, equal to Mirum's closing trading price on the grant date. They will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both are subject to continued employment and the terms of Mirum's 2020 Inducement Plan.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
What is the focus of Mirum Pharmaceuticals, Inc.?
What is Maralixibat used for?
Where is Mirum Pharmaceuticals headquartered?
What is Livmarli?
When was Mirum Pharmaceuticals founded?
What is Volixibat being developed for?
What are the recent achievements of Mirum Pharmaceuticals?
How does Mirum Pharmaceuticals contribute to the biopharmaceutical industry?
How can I get the latest updates on Mirum Pharmaceuticals?
What products are in Mirum Pharmaceuticals' pipeline?
